About Us

Dr. Mark Kester was a pioneer in introducing nanoscience into the medical field. A visionary to translate nanotechnology into clinical medical practice. He founded KestoneNano and various other cooperations to translate nanotechnology into clinical medicine. We strive to carry forward his legacy, now that he is no longer with us.

Our lab offers nanoscale “solutions” for therapeutics, improving pharmacokinetics, bioavailability and toxicological profiles through targeted delivery. In addition, we also “re-formulate” oncological, neurological and metabolic drugs to increase and extend IP protection. In addition to designing RNA nanoformulations using LNP technology, we can also engineer less toxic platforms using pH-responsive, ionizable nanoliposomes, which change charge as a function of pH to offer enhanced loading and defined release capabilities. We can also design uncharged calcium phosphate NanoParticles (NanoJackets) to bind and deliver oligonucleotides. Furthermore, we have an inventory of multiple lipid and polymer nanoparticles, including drug-lipid conjugates (DLCs), designed for small molecules that can be readily adapted for RNA protection and delivery. Our DLC formulations are especially useful to cross membrane barriers, such as the Blood Brain Barrier, and to reduce P-glyco-protein mediated drug resistance, characteristics useful for treating glioblastomas, Alzheimer’s Disease and traumatic brain injuries. Overall, our team of faculty and researchers offers strong nanoformulation capabilities coupled with outstanding physio-chemical characterization instrumentation, through our nanoMaterial Characterization Facility (NMCF), to achieve the design and scale-up of nanoparticles suitable for delivery of all drug types.